Evidence map›Paper›PMID 31307990›Full record

ArticleAntimicrobial agents and chemotherapy2019

Rapid Identification of New Delhi Metallo-β-Lactamase (NDM) Using Tryptic Peptides and LC-MS/MS.

Honghui Wang, Jeffrey R Strich, Steven K Drake, Yong Chen, Jung-Ho Youn, Avi Z Rosenberg, Marjan Gucek, John P Dekker, Anthony F Suffredini

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Metabolism-Based Biomarkers for Rapid Phenotypic Antibiotic Susceptibility Testing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Modified ELISA for Ultrasensitive Diagnosis.Journal of clinical medicine · 2021
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Honghui WangCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Jeffrey R StrichCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Steven K DrakeCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Yong ChenProteomics Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Jung-Ho YounDepartment of Laboratory Medicine, Clinical Center, Microbiology Service, National Institutes of Health, Bethesda, Maryland, USA.
Avi Z RosenbergKidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Marjan GucekProteomics Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
John P Dekker *Department of Laboratory Medicine, Clinical Center, Microbiology Service, National Institutes of Health, Bethesda, Maryland, USA.
Anthony F Suffredini *Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA asuffredini@cc.nih.gov.

Funding

Proteomics CoreZICHL005903 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI GUCEK, MARJAN · 2009 to 2022
$23.3M
Novel Applications of Mass Spectrometry and Proteomics to Infectious Disease DiagnosticsZIAAI001252 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DEKKER, JOHN · 2019 to 2020
$742k
6 · The paper itself

Abstract

There is significant interest in the development of mass spectrometry (MS) methods for antimicrobial resistance protein detection, given the ability of these methods to confirm protein expression. In this work, we studied the performance of a liquid chromatography, tandem MS multiple-reaction monitoring (LC-MS/MS MRM) method for the direct detection of the New Delhi metallo-β-lactamase (NDM) carbapenemase in clinical isolates. Using a genoproteomic approach, we selected three unique peptides (SLGNLGDADTEHYAASAR, AFGAAFPK, and ASMIVMSHSAPDSR) specific to NDM that were efficiently ionized and spectrally well-defined. These three peptides were used to build an assay with turnaround time of 90 min. In a blind set, the assay detected 21/24

Indexed as

Gene Expression Regulation, BacterialAmino Acid SequenceAnti-Bacterial Agentsbeta-Lactamasesbeta-Lactam Resistancebeta-LactamsBiological AssayChromatography, LiquidIsoenzymesKlebsiella pneumoniaeMicrobial Sensitivity TestsPeptide MappingPeptidesPlasmidsProteolysisTandem Mass SpectrometryAnti-Bacterial Agentsbeta-lactamase NDM-1beta-Lactamasesbeta-LactamsIsoenzymesPeptidesTrypsinmass spectrometrymultiple-reaction monitoringNew Delhi metallo-β-lactamasetryptic peptide

Identifiers

PMID31307990
PMCPMC6709477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.